Gni Group Ltd. · TSE:2160

Gni — Q1 FY2021 Earnings Presentation

7 slides from Gni's earnings presentation, May 19, 2021

  1. Slide 1: GNI Group Ltd. Q1 FY2021 Financial Results Corporate Presentation

    Glre PD: GNI Group Ltd. Q1 FY2021 Financial Results Corporate Presentation May 19, 2021 a Securities Code: 2160

  2. Slide 2: Forward-looking Statements

    Give Forward-looking Statements This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements.

  3. Slide 3: FY2021 — Q1 Highlights

    Give FY2021 — Q1 Highlights v Year on year increase in both Revenue and Quarterly Profit - Strong revenue trend for Etuary® - Revenue and profitability recovery of Medical Device Segment ¥ Acquired the remaining of shares of Berkeley Advanced Biomaterials LLC(BAB) to make it a wholly owned subsidiar

  4. Slide 4: FY2021-Q1 Consolidated Financial Results Comparison (YoY)

    We Bring New Hope to Patients GIss FY2021-Q1 Consolidated Financial Results Comparison (YoY) Million yen : Amounts of less than one million yen are rounded down Statements of Income haga halon Change Revenue 2,125 3,872 82.2% Gross profit 1,748 3,416 95.4% Selling, general and administrative expense

  5. Slide 5: Revenue Growth Trend

    Give Revenue Growth Trend Index:2017 Q1 Revenue =100 4,200 Contributed additional sales and profits to GNI Group's 1,106 positive operating results Scene Sa | a Jmajorty stake n BAB | stake in BAB") 735, 800 600 400 FY2017 FY2018 FY2019 FY2020 FY2021 Qi Q2 Q3 a4 Qi Q2 Q3 Q4 Qi Q2 Q3 Q4 Qi Q2 Q3 Q4 Q

  6. Slide 6: Development Pipeline Update

    We Bring New Hope to Patients GIs Development : Pipeline Update Product - Indication Origin Phase | Phase ll Phase Ill test Status Etuary® (China) . Terie Lana Disnee (CIID) Proprietary tS — | Dual Phase Ill clinical trials ongoing. Proceeding smoothly - Radiation Pneumonitis (RP) Proprietary Expand

  7. Slide 7: Contact Information

    We Bring New Hope to Patients GIs Contact Information infojapan@gnipharma.com © 2021 GNI Group Ltd. All rights reserved 7

GNI Group — Q1 FY2021 Earnings Presentation on 6ix